



Update to Liquidia's Participation in the Jefferies Healthcare Conference

June 7, 2022

MORRISVILLE, N.C., June 07, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today an update to the company's participation in the Jefferies Healthcare Conference. Mr. Michael Kaseta, Chief Financial Officer, will participate in a fireside chat on Thursday, June 9, 2022, now scheduled for 8:00 am Eastern Time. The conference is taking place June 8-10, 2022, in New York City.

A webcast of the event will be available on the investors section of Liquidia's website at <https://liquidia.com/investors/events-and-presentations>, and will be archived for 30 days following the event.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT[®] Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA[™] (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.

Contact Information for Media & Investors

Jason Adair
Senior Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com

 Primary Logo

Source: Liquidia Corporation